Business Wire

MI-EATON

Share
Eaton to Display Terminals and Connectors at CONEXPO-CON/AGG Trade Show

Intelligent power management company Eaton today announced it will be displaying its line of power connectors and terminals for electrified and internal combustion construction and off-highway vehicles at the CONEXPO-CON/AGG construction trade show March 14-18 in Las Vegas.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230309005192/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Royal Power Solutions large LP12, LP16 and RD14 terminals are designed for vehicles typically used in construction and off-highway fields. (Photo: Business Wire)

The connectors were designed and developed by Royal Power Solutions (RPS), which Eaton acquired in 2022. Established in 1938, RPS is a global leader in the development and production of critical high-precision power- and signal-distribution terminals and connectors.

“The construction industry, like many others, is transitioning to electrification. Eaton’s global and diverse footprint has broadened our reach and ability to grow in this market,” said Chris Mancuso, general manager, Power Connections, Eaton’s eMobility business. “As the construction industry electrifies, the need for differentiating terminals and connectors evolves in parallel. We have seen a similar transition in the automotive market.”

Eaton’s portfolio of industry-leading electrical solutions includes terminals, connectors and other electrical components designed to handle current levels up to 500 amps. Among those components are stamped battery and eyelet terminals that can withstand vibration and harsh environments, making them ideal for commercial and off-highway vehicles.

High Power Lock Box connectors provide protection, superior performance

Eaton’s high power lock box (HPLB) power connectors are ideal for current and future electrified construction and off-highway vehicle solutions and can help reduce common warranty issues. The HPLB connectors offer a space-saving profile, superior performance, cost savings and reduced manufacturing complexity. The HPLB terminals provide efficiency, reliability and have stronger current carrying capabilities compared to terminals on the market today.

The HPLB terminal system forms a connection in a unique way that provides improved contact force as the temperature increases. Unlike traditional competitors’ box-and-blade or pin-and-socket terminal connections, Eaton’s HPLB terminals use an inverted contact system approach for a stronger connection.

Terminals designed for construction, aggregate industries

Part of the HPLB product line, the low-profile 12 (LP12), low-profile 16 (LP16) and round 14 (RD14) terminals are larger and designed for vehicles typically used in construction and agricultural fields. Able to carry up to 500 amps, the HPLB terminals allow global customers to simplify the manufacturing process and open new areas of opportunity for electrified off-highway vehicles.

Busbars feature low profile, flexibility to meet design requirements

Another technology now available to Eaton’s construction and off-highway vehicle customers is RigiFlex busbars, which can be manufactured in copper or aluminum, depending on customer requirements. With a unique, simple, single piece flow manufacturing process, Eaton can scale volume to meet any customer specification.

The RigiFlex busbar is rigid in some areas, but flexible in sections that require expansion, contraction or elevated changes in the system design. This flexibility also works well across the battery pack in areas that need to comply with expansion and contraction during charging and discharging cycles due to changing cell thicknesses.

Low-profile busbars enable space-efficient design without heat sinks for weight savings. Eaton also can produce busbars with a level of flatness over length unmatched by competitors.

“When off-highway equipment is assembled, it’s largely done manually since robots have difficulty handling round wires, which are hard for them to grasp,” Mancuso said. “When employing high power lock box terminals our Rigiflex busbars improve the assembly process, safety and time to complete the manufacturing process and with less equipment and fewer assembly personnel.”

Eaton is an intelligent power management company dedicated to improving the quality of life and protecting the environment for people everywhere. We are guided by our commitment to do business right, to operate sustainably and to help our customers manage power ─ today and well into the future. By capitalizing on the global growth trends of electrification and digitalization, we’re accelerating the planet’s transition to renewable energy, helping to solve the world’s most urgent power management challenges, and doing what’s best for our stakeholders and all of society.

Founded in 1911, Eaton is marking its 100th anniversary of being listed on the New York Stock Exchange. We reported revenues of $20.8 billion in 2022 and serve customers in more than 170 countries. For more information, visit www.eaton.com. Follow us on Twitter and LinkedIn.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230309005192/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye